Miscellaneous Urogenital Disorders

Hydralazine Linked to Amenorrhea in Premenopausal Patient

By September 18, 2018

This case highlights a possible relationship between the administration of hydralazine and the development of amenorrhea.

Caffeine Consumption Appears to Reduce the Risk of Death in CKD Patients

By September 12, 2018

Using data from the National Health and Nutrition Examination Survey (1999-2010), researchers evaluated caffeine consumption among 4863 non-institutionalized adults with CKD to determine the association between caffeine intake and mortality in these patients.

Efficacy, Safety of PSA Testing for Prostate Cancer Screening Investigated

September 06, 2018

Odds of choosing screening up for men with family history, African descent, low socioeconomic status

Nalbuphine Can Relieve Opioid-Induced Urine Retention

September 04, 2018

During the first 6 hours after receiving the drug, the patient voided 850mL, and pain remained controlled. On ultrasonography, bladder volume was 77mL one day later.

Keytruda, Tecentriq Labeling Updated With PD-L1 Testing Requirements

By August 17, 2018

The Dako PD-L1 IHC 22C3 PharmDx Assay has been approved as a companion diagnostic to identify patients with with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for treatment with Keytruda.

Vicinium Fast-Tracked for Non-Muscle Invasive Bladder Cancer

By August 10, 2018

A Phase 3 trial (Vista) of the treatment is currently taking place; the trial is evaluating the treatment in patients with NMIBC who have previously received 2 courses of BCG and who are now BCG-unresponsive.

Tamsulosin Does Not Appear to Promote Urinary Stone Passage

August 01, 2018

The researchers found that stone passage rates were 50% in the tamsulosin group and 47% in the placebo group (relative risk, 1.05; 95.8% confidence interval, 0.87 to 1.27; P=.60).

FDA Clears Smartphone-Enabled Urinalysis Kit for Home Use

By July 25, 2018

The Dip.io kit works in tandem with existing smartphone cameras and a dedicated app.

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

By July 17, 2018

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

FDA Approves Expanded Prostate Cancer Indication for Xtandi

By July 16, 2018

The approval was based on data from the Phase 3 PROSPER trial which enrolled 1401 patients with non-metastatic CRPC.

Does Metformin Use Increase the Risk of Acidosis in CKD?

July 12, 2018

Time-dependent metformin use was not associated with incident acidosis overall or in those with eGFR 45 to 59 and 30 to 44 mL/min/1.73 m² (aHR, 1.16 [95% CI, 0.95 to 1.41] and 1.09 [95% CI, 0.83 to 1.44]) compared with alternative diabetes management.

Higher Visceral Fat Ratio Seen With Recurring Urolithiasis

July 09, 2018

However, there was no significant difference in visceral fat area (P=.32), subcutaneous fat area (P=.36), visceral fat volume (P=.38), or subcutaneous fat volume (P=.23).

FDA Permits Marketing of Devices to Create Arteriovenous Fistula

July 05, 2018

Two devices designed to create arteriovenous fistula in patients with CKD in need of hemodialysis

Nitric Oxide Cuts Kidney Injury After Long Cardiac Surgery

July 02, 2018

Reduced kidney injury, better kidney function seen after prolonged cardiopulmonary bypass

New Technique Allows Rapid Bedside Measurement of GFR

June 29, 2018

"The VFI-based approach allows for the rapid determination of mGFR at the bedside while maintaining patient safety and measurement accuracy and reproducibility," the authors write.

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

By June 20, 2018

In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

By June 12, 2018

According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.

Drug Use Tied to Early Death, Kidney Disease Progression

June 11, 2018

Over the study period, compared with non-smoking throughout follow-up, the multivariable-adjusted hazard ratios were 1.02 (95% confidence interval [CI], 0.86 to 1.21) for CKD progression and 1.86 (95% CI, 1.54 to 2.24) for all-cause mortality for persistent tobacco smoking.

Combo Therapy Appears Effective for Treating Subfertile Men

By June 06, 2018

To evaluate safety and efficacy of this therapy, study authors gathered data on patients treated with the combination from 2014 to 2017.

Positive Results Announced for First-in-Class Metabolic Acidosis Treatment

By June 05, 2018

After 12 weeks, 59.2% of patients treated with the study drug saw an increased blood bicarbonate of ≥4mEq/L or achieved a level in the normal range (22 to 29mEq/L) vs 22.5% of patients in the placebo group (primary endpoint; P <.0001).

Raviten Gets Fast Track Status for Intradialytic Hypotension Management

By May 29, 2018

Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.

Yonsa Approved for Metastatic Castration-Resistant Prostate Cancer

By May 23, 2018

The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.

FDA: PD-L1 Blocking Agents Linked to Decreased Survival in Urothelial Cancer Trials

By May 21, 2018

Data Monitoring Committees (DMC) from two ongoing clinical trials (KEYNOTE-361 and IMVIGOR-130) found that in the monotherapy arms of these studies, patients with low PD-L1 status had decreased survival compared with those who received cisplatin- or carboplatin-based chemotherapy.

AUA: Most Women Report Dysfunctional Toileting Behaviors

May 21, 2018

Overall, 79.9, 64.5, and 97.8% reported premature voiding, straining to void, and delayed voiding, respectively.

Acute Kidney Injury in Hospital Ups Risk of Later Heart Failure

May 18, 2018

AKI was independently associated with higher rates of the composite outcome of hospitalization for heart failure and atherosclerotic events 1-year post-discharge.

Early Post-Op APAP Exposure May Cut AKI Risk in Peds Cardiac Sx

May 15, 2018

Acetaminophen exposure was protective against postoperative AKI after adjustment for multiple confounding variables (odds ratio, 0.86 per each additional 10mg/kg).

Postresection intravesical gemcitabine decreases non-muscle-invasive urothelial CA recurrence

May 11, 2018

In this randomized controlled trial, time to recurrence was lower in patient with non-muscle-invasive urothelial cancer when treated with intravesical gemcitabine as compared to saline controls.

Sofosbuvir Improves Renal Safety in Patients With Chronic Hep C

May 11, 2018

In patients with glomerular filtration rate (GFR) ≥45 mL/min/1.73 m² there was significant improvement in renal biomarkers, as indicated by a progressive increase in mean GFR values until 1 year.

Recent Oral Antibiotics Use Tied to Higher Risk of Nephrolithiasis

May 11, 2018

The strength of these associations was greatest for exposures at younger ages (P<.001) and 3 to 6 months before the index date (P<.001), with all but broad-spectrum penicillins remaining statistically significant 3 to 5 years from exposure.

Can coaching improve water intake, outcomes in those with chronic disease?

May 09, 2018

In this randomized controlled trial, coaching to improve daily fluid intake did not improve kidney function in patients with Chronic Kidney Disease.